Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Urvashi Surti is active.

Publication


Featured researches published by Urvashi Surti.


Nature Biotechnology | 2003

Large-scale genotyping of complex DNA

Giulia C. Kennedy; Hajime Matsuzaki; Shoulian Dong; Wei-Min Liu; Jing Huang; Guoying Liu; Xing Su; Manqiu Cao; Wenwei Chen; Jane Zhang; Weiwei Liu; Geoffrey Yang; Xiaojun Di; Thomas B. Ryder; Zhijun He; Urvashi Surti; Michael S. Phillips; Michael T. Boyce-Jacino; Stephen P. A. Fodor; Keith W. Jones

Genetic studies aimed at understanding the molecular basis of complex human phenotypes require the genotyping of many thousands of single-nucleotide polymorphisms (SNPs) across large numbers of individuals. Public efforts have so far identified over two million common human SNPs; however, the scoring of these SNPs is labor-intensive and requires a substantial amount of automation. Here we describe a simple but effective approach, termed whole-genome sampling analysis (WGSA), for genotyping thousands of SNPs simultaneously in a complex DNA sample without locus-specific primers or automation. Our method amplifies highly reproducible fractions of the genome across multiple DNA samples and calls genotypes at >99% accuracy. We rapidly genotyped 14,548 SNPs in three different human populations and identified a subset of them with significant allele frequency differences between groups. We also determined the ancestral allele for 8,386 SNPs by genotyping chimpanzee and gorilla DNA. WGSA is highly scaleable and enables the creation of ultrahigh density SNP maps for use in genetic studies.


Nature Genetics | 2010

A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay

Santhosh Girirajan; Jill A. Rosenfeld; Gregory M. Cooper; Francesca Antonacci; Priscillia Siswara; Andy Itsara; Laura Vives; Tom Walsh; Shane McCarthy; Carl Baker; Mefford Hc; Jeffrey M. Kidd; Sharon R. Browning; Brian L. Browning; Diane E. Dickel; Deborah L. Levy; Blake C. Ballif; Kathryn Platky; Darren M. Farber; Gordon C. Gowans; Jessica J. Wetherbee; Alexander Asamoah; David D. Weaver; Paul R. Mark; Jennifer N. Dickerson; Bhuwan P. Garg; Sara Ellingwood; Rosemarie Smith; Valerie Banks; Wendy Smith

We report the identification of a recurrent, 520-kb 16p12.1 microdeletion associated with childhood developmental delay. The microdeletion was detected in 20 of 11,873 cases compared with 2 of 8,540 controls (P = 0.0009, OR = 7.2) and replicated in a second series of 22 of 9,254 cases compared with 6 of 6,299 controls (P = 0.028, OR = 2.5). Most deletions were inherited, with carrier parents likely to manifest neuropsychiatric phenotypes compared to non-carrier parents (P = 0.037, OR = 6). Probands were more likely to carry an additional large copy-number variant when compared to matched controls (10 of 42 cases, P = 5.7 × 10−5, OR = 6.6). The clinical features of individuals with two mutations were distinct from and/or more severe than those of individuals carrying only the co-occurring mutation. Our data support a two-hit model in which the 16p12.1 microdeletion both predisposes to neuropsychiatric phenotypes as a single event and exacerbates neurodevelopmental phenotypes in association with other large deletions or duplications. Analysis of other microdeletions with variable expressivity indicates that this two-hit model might be more generally applicable to neuropsychiatric disease.


American Journal of Obstetrics and Gynecology | 1978

The syndromes of hydatidiform mole: I. Cytogenetic and morphologic correlations

Aron E. Szulman; Urvashi Surti

Cytogenetic and morphologic analysis of 23 hydatidiform moles allowed the division into at least two syndromes: (1) the syndrome of complete (classical) mole is without an ascertainable embryo/fetus, gives a diploid karyotype, and manifests a progressive fluid engorgement of the villi as well as a gross, haphazardly distributed trophoblastic hyperplasia; (2) the syndrome of partial (incomplete) mole has an ascertainable fetus (alive or dead), gives a triploid karyotype, and exhibits a slowly progressing hydatidiform swelling in the presence of functioning villous capillaries that spares many villi; trophoblastic immaturity is constant and focal hyperplasia is inconspicuous but present. A single case of diploid mole with unusual morphologic features, complete with a fetus, may herald yet another syndrome. Human chorionic gonadotropin levels were initially high in practically all cases. There was no malignant trophoblastic disease in this small series, but a plea is made that partial moles be followed carefully in order to establish their relation to choriocarcinoma.


American Journal of Human Genetics | 2010

Deletion 17q12 Is a Recurrent Copy Number Variant that Confers High Risk of Autism and Schizophrenia

Daniel Moreno-De-Luca; Jennifer G. Mulle; Erin B. Kaminsky; Stephan J. Sanders; Scott M. Myers; Margaret P Adam; Amy T. Pakula; Nancy J. Eisenhauer; Kim Uhas; LuAnn Weik; Lisa Guy; Melanie Care; Chantal Morel; Charlotte Boni; Bonnie Anne Salbert; Ashadeep Chandrareddy; Laurie A. Demmer; Eva W.C. Chow; Urvashi Surti; Swaroop Aradhya; Diane L. Pickering; Denae M. Golden; Warren G. Sanger; Emily Aston; Arthur R. Brothman; Troy J. Gliem; Erik C. Thorland; Todd Ackley; Ram Iyer; Shuwen Huang

Autism spectrum disorders (ASD) and schizophrenia are neurodevelopmental disorders for which recent evidence indicates an important etiologic role for rare copy number variants (CNVs) and suggests common genetic mechanisms. We performed cytogenomic array analysis in a discovery sample of patients with neurodevelopmental disorders referred for clinical testing. We detected a recurrent 1.4 Mb deletion at 17q12, which harbors HNF1B, the gene responsible for renal cysts and diabetes syndrome (RCAD), in 18/15,749 patients, including several with ASD, but 0/4,519 controls. We identified additional shared phenotypic features among nine patients available for clinical assessment, including macrocephaly, characteristic facial features, renal anomalies, and neurocognitive impairments. In a large follow-up sample, the same deletion was identified in 2/1,182 ASD/neurocognitive impairment and in 4/6,340 schizophrenia patients, but in 0/47,929 controls (corrected p = 7.37 × 10⁻⁵). These data demonstrate that deletion 17q12 is a recurrent, pathogenic CNV that confers a very high risk for ASD and schizophrenia and show that one or more of the 15 genes in the deleted interval is dosage sensitive and essential for normal brain development and function. In addition, the phenotypic features of patients with this CNV are consistent with a contiguous gene syndrome that extends beyond RCAD, which is caused by HNF1B mutations only.


Nature Genetics | 2007

Discovery of a previously unrecognized microdeletion syndrome of 16p11.2–p12.2

Blake C. Ballif; Sara A Hornor; Elizabeth A. Jenkins; Suneeta Madan-Khetarpal; Urvashi Surti; Kelly E. Jackson; Alexander Asamoah; Pamela Brock; Gordon C. Gowans; Robert Conway; John M. Graham; Livija Medne; Elaine H. Zackai; Tamim H. Shaikh; Joel Geoghegan; Rebecca R. Selzer; Peggy S. Eis; Bassem A. Bejjani; Lisa G. Shaffer

We have identified a recurrent de novo pericentromeric deletion in 16p11.2–p12.2 in four individuals with developmental disabilities by microarray-based comparative genomic hybridization analysis. The identification of common clinical features in these four individuals along with the characterization of complex segmental duplications flanking the deletion regions suggests that nonallelic homologous recombination mediated these rearrangements and that deletions in 16p11.2–p12.2 constitute a previously undescribed syndrome.


Genes, Chromosomes and Cancer | 2007

EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma

Cristina R. Antonescu; Paola Dal Cin; Khedoudja Nafa; Lisa A. Teot; Urvashi Surti; Christopher D. M. Fletcher; Marc Ladanyi

The molecular hallmark of angiomatoid fibrous histiocytoma (AFH) is not well defined, with only six cases with specific gene fusions reported to date, consisting of either FUS‐ATF1 or EWSR1‐ATF1. To address this, we investigated the presence of FUS‐ATF1, EWSR1‐ATF1, and the highly related EWSR1‐CREB1 fusion in a group of nine AFHs. All cases were subjected to RT‐PCR for EWSR1‐ATF1 and EWSR1‐CREB1. FISH for EWSR1 and FUS rearrangements was performed in most cases. Transcriptional profiling was performed in three tumors and their gene expression was compared to five clear cell sarcomas expressing either the EWSR1‐ATF1 or EWSR1‐CREB1 fusion. By RT‐PCR, eight out of nine tumors showed the presence of the EWSR1‐CREB1 fusion, while one had an EWSR1‐ATF1 transcript. FISH showed evidence of EWSR1 rearrangement in seven out of eight cases. Karyotypic analysis performed in one tumor showed a t(2;22)(q33;q12). High transcript levels were noted for TFE3 in AFH tumors, while overexpression of genes involved in melanogenesis, such as MITF, GP100, and MET was noted in somatic clear cell sarcomas. We report for the first time the presence of EWSR1‐CREB1 in AFH, which now appears to be the most frequent gene fusion in this tumor. EWSR1‐CREB1 is a novel translocation recently described in clear cell sarcoma of the GI tract. EWSR1‐ATF1, identified in some AFH cases, is the most common genetic abnormality in soft tissue clear cell sarcoma. Thus, identical fusions involving ATF1 and CREB1 are found in two distinct sarcomas, which may be able to transform two different types of mesenchymal precursor cells, unlike most other sarcoma gene fusions.


Proceedings of the National Academy of Sciences of the United States of America | 2010

High-resolution human genome structure by single-molecule analysis

Brian Teague; Michael S. Waterman; Steven Goldstein; Konstantinos Potamousis; Shiguo Zhou; Susan Reslewic; Deepayan Sarkar; Anton Valouev; Chris Churas; Jeffrey M. Kidd; Scott Kohn; Rodney Runnheim; Casey Lamers; Dan Forrest; Michael A. Newton; Evan E. Eichler; Marijo Kent-First; Urvashi Surti; Miron Livny; David C. Schwartz

Variation in genome structure is an important source of human genetic polymorphism: It affects a large proportion of the genome and has a variety of phenotypic consequences relevant to health and disease. In spite of this, human genome structure variation is incompletely characterized due to a lack of approaches for discovering a broad range of structural variants in a global, comprehensive fashion. We addressed this gap with Optical Mapping, a high-throughput, high-resolution single-molecule system for studying genome structure. We used Optical Mapping to create genome-wide restriction maps of a complete hydatidiform mole and three lymphoblast-derived cell lines, and we validated the approach by demonstrating a strong concordance with existing methods. We also describe thousands of new variants with sizes ranging from kb to Mb.


American Journal of Human Genetics | 1997

Familial Skewed X Inactivation: A Molecular Trait Associated with High Spontaneous-Abortion Rate Maps to Xq28

Elena Pegoraro; Jeanette Whitaker; Patricia Mowery-Rushton; Urvashi Surti; Mark C. Lanasa; Eric P. Hoffman

We report a family ascertained for molecular diagnosis of muscular dystrophy in a young girl, in which preferential activation (> or = 95% of cells) of the paternal X chromosome was seen in both the proband and her mother. To determine the molecular basis for skewed X inactivation, we studied X-inactivation patterns in peripheral blood and/or oral mucosal cells from 50 members of this family and from a cohort of normal females. We found excellent concordance between X-inactivation patterns in blood and oral mucosal cell nuclei in all females. Of the 50 female pedigree members studied, 16 showed preferential use (> or = 95% cells) of the paternal X chromosome; none of 62 randomly selected females showed similarly skewed X inactivation was maternally inherited in this family. A linkage study using the molecular trait of skewed X inactivation as the scored phenotype localized this trait to Xq28 (DXS1108; maximum LOD score [Zmax] = 4.34, recombination fraction [theta] = 0). Both genotyping of additional markers and FISH of a YAC probe in Xq28 showed a deletion spanning from intron 22 of the factor VIII gene to DXS115-3. This deletion completely cosegregated with the trait (Zmax = 6.92, theta = 0). Comparison of clinical findings between affected and unaffected females in the 50-member pedigree showed a statistically significant increase in spontaneous-abortion rate in the females carrying the trait (P < .02). To our knowledge, this is the first gene-mapping study of abnormalities of X-inactivation patterns and is the first association of a specific locus for recurrent spontaneous abortion in a cytogenetically normal family. The involvement of this locus in cell lethality, cell-growth disadvantage, developmental abnormalities, or the X-inactivation process is discussed.


The New England Journal of Medicine | 2011

Noninvasive prenatal diagnosis of a fetal microdeletion syndrome.

David G. Peters; Tianjiao Chu; Svetlana A. Yatsenko; Nancy W. Hendrix; W. Allen Hogge; Urvashi Surti; Kimberly Bunce; Mary K. Dunkel; Patricia Shaw; Aleksandar Rajkovic

This proof-of-principle study shows that it is possible to detect a genetic microdeletion carried by a fetus through analysis of DNA in circulating maternal blood.


PLOS ONE | 2012

Whole Exome Sequencing in a Random Sample of North American Women with Leiomyomas Identifies MED12 Mutations in Majority of Uterine Leiomyomas

Megan M. McGuire; Alexander N. Yatsenko; Lori Hoffner; Mirka W. Jones; Urvashi Surti; Aleksandar Rajkovic

Uterine leiomyomas (uterine fibroids) arise from smooth muscle tissue in the majority of women by age 45. It is common for these clonal tumors to develop from multiple locations within the uterus, leading to a variety of symptoms such as pelvic pain, abnormal uterine bleeding, and infertility. We performed whole exome sequencing on genomic DNA from five pairs of leiomyomas and corresponding normal myometrium to determine genetic variations unique to leiomyomas. Whole exome sequencing revealed that the gene encoding transcription factor MED12 (Mediator complex subunit 12) harbored heterozygous missense mutations caused by single nucleotide variants in highly conserved codon 44 of exon 2 in two of five leiomyomas. Sanger re-sequencing of MED12 among these five leiomyomas confirmed the two single nucleotide variants and detected a 42 base-pair deletion within exon 2 of MED12 in a third leiomyoma. MED12 was sequenced in an additional 143 leiomyomas and 73 normal myometrial tissues. Overall, MED12 was mutated in 100/148 (67%) of the genotyped leiomyomas: 79/148 (53%) leiomyomas exhibited heterozygous missense single nucleotide variants, 17/148 (11%) leiomyomas exhibited heterozygous in-frame deletions/insertion-deletions, 2/148 (1%) leiomyomas exhibited intronic heterozygous single nucleotide variants affecting splicing, and 2/148 (1%) leiomyomas exhibited heterozygous deletions/insertion-deletions spanning the intron 1-exon 2 boundary which affected the splice acceptor site. Mutations were not detected in MED12 in normal myometrial tissue. MED12 mutations were equally distributed among karyotypically normal and abnormal uterine leiomyomas and were identified in leiomyomas from both black and white American women. Our studies show an association between MED12 mutations and leiomyomas in ethnically and racially diverse American women.

Collaboration


Dive into the Urvashi Surti's collaboration.

Researchain Logo
Decentralizing Knowledge